Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs

Ítems similars

• Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
  per: Deodhar, Malavika, et al.
  Publicat: (2020)
• Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
  per: Sweilem B. Al Rihani, et al.
  Publicat: (2020-08-01)
• Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
  per: Al Rihani, Sweilem B., et al.
  Publicat: (2020)
• ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System
  per: Michaud, Veronique, et al.
  Publicat: (2020)
• Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
  per: Smith, Matt K., et al.
  Publicat: (2021)